HDL Size is More Accurate than HDL Cholesterol to Predict Carotid Subclinical Atherosclerosis in Individuals Classified as Low Cardiovascular Risk
暂无分享,去创建一个
Vanessa Helena de Souza Zago | Eliane Soler Parra | Fernanda Alexandre | E. D. de Faria | A. Sposito | Natalia Baratella Panzoldo | Daniel Zanetti Scherrer | Jamal Bakkarat | Valeria Sutti Nunes | Edna Regina Nakandakare | Eder Carlos Rocha Quintão | Wilson Nadruz-Jr | Eliana Cotta de Faria | Andrei C. Sposito | V. Nunes | E. Nakandakare | F. Alexandre | V. H. Zago | N. Panzoldo | E. Quintão | E. Parra | D. Z. Scherrer | Jamal Bakkarat | Wilson Nadruz-Jr
[1] Bernd Holleczek,et al. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. , 2013, European heart journal.
[2] Ian Graham,et al. How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[3] C. Ehnholm,et al. Preparation, characterization, and measurement of hepatic lipase. , 1986, Methods in enzymology.
[4] E. Ros,et al. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[5] M. Jauhiainen,et al. Determination of human plasma phospholipid transfer protein mass and activity. , 2005, Methods.
[6] N. Wareham,et al. High-Density Lipoprotein Particle Size and Concentration and Coronary Risk , 2009, Annals of Internal Medicine.
[7] A. Kontush,et al. Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[8] José A Fernández,et al. Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology. , 2009, Biochimica et biophysica acta.
[9] Samia Mora,et al. Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women , 2009, Circulation.
[10] V. Dias,et al. Dual-precipitation method evaluated for determination of high-density lipoprotein (HDL), HDL2, and HDL3 cholesterol concentrations. , 1988, Clinical chemistry.
[11] D. Freedman,et al. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. , 2002, The American journal of cardiology.
[12] R. Devries,et al. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. , 2003 .
[13] W. Sluiter,et al. Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. , 2008, The Journal of clinical endocrinology and metabolism.
[14] M. Jauhiainen,et al. Dietary determinants of serum paraoxonase activity in healthy humans. , 2002, Atherosclerosis.
[15] E. Vicaut,et al. Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004–2006–2011) , 2012, Cerebrovascular Diseases.
[16] A. Gebre,et al. Characterization of C-terminal histidine-tagged human recombinant lecithin:cholesterol acyltransferase. , 1999, Journal of lipid research.
[17] J. Frohlich,et al. Cholesterol esterification rate in plasma depleted of very low and low density lipoproteins is controlled by the proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle-aged and septuagenarian men. , 1992, Journal of lipid research.
[18] R. Dullaart,et al. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. , 2003, Clinical laboratory.
[19] G. Dallinga-Thie,et al. Plasma phospholipid transfer protein activity is independently determined by obesity and insulin resistance in non-diabetic subjects. , 2011, Atherosclerosis.
[20] A. Sposito,et al. Most of the patients presenting myocardial infarction would not be eligible for intensive lipid-lowering based on clinical algorithms or plasma C-reactive protein. , 2011, Atherosclerosis.
[21] R. Maranhão,et al. Rapid, simple laser-light-scattering method for HDL particle sizing in whole plasma. , 2004, Clinical chemistry.
[22] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[23] S. Hazen,et al. Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[24] Robert L Wilensky,et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.
[25] Ji-Young Lee,et al. Functional LCAT deficiency in human apolipoprotein A-I transgenic, SR-BI knockout mice Published, JLR Papers in Press, February 1, 2007. , 2007, Journal of Lipid Research.
[26] A. Jonas,et al. Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI. , 2001, Journal of lipid research.
[27] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[28] W. J. Johnson,et al. High Density Lipoprotein Phospholipid Composition Is a Major Determinant of the Bi-directional Flux and Net Movement of Cellular Free Cholesterol Mediated by Scavenger Receptor BI* , 2000, The Journal of Biological Chemistry.
[29] L. Lagrost,et al. Determination of the mass concentration and the activity of the plasma cholesteryl ester transfer protein (CETP). , 1998, Methods in molecular biology.
[30] New insights on the simultaneous assessment of insulin sensitivity and beta-cell function with the HOMA2 method. , 2006, Diabetes care.
[31] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[32] S. Yamashita,et al. Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia DOI 10.1194/jlr.M100349-JLR200 , 2002, Journal of Lipid Research.
[33] R. Dullaart,et al. Alterations in high‐density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins , 2003, European journal of clinical investigation.
[34] E. Vicaut,et al. Mannheim Carotid Intima-Media Thickness Consensus (2004–2006) , 2006, Cerebrovascular Diseases.
[35] H. Kahn,et al. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison , 2005, BMC cardiovascular disorders.